Intussusception following rotavirus vaccine administration: Post-marketing surveillance in the National Immunization Program in Australia

Buttery, James Peter; Danchin, Margie; Lee, Katherine; Carlin, John B.; McIntyre, Peter; Elliott, Elizabeth J; Booy, Robert; Bines, Julie E

doi:10.1016/j.vaccine.2011.01.088

Cited by 252 publications

(137 citation statements)

References 22 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…The German Standing Committee on Vaccination (STIKO, Ständige Impfkommission) published its recommendation that infants should receive RV vaccination in August 2013. Based on data from observational studies available at that time, the risk was estimated to be 1 to 2 additional intussusceptions per 100 000 vaccinated infants, irrespective of which vaccine was used (13)(14)(15)(16)(17)(18)(19)(20)(21)(22). STIKO states explicitly that the vaccination is associated with a slightly increased risk of intussusception during the first week after the first dose of vaccine.…”

mentioning

confidence: 99%

Risk of Intussusception After Rotavirus Vaccination

Koch¹,

Harder²,

Kries³

et al. 2017

Deutsches Ärzteblatt International

View full text Add to dashboard Cite

SUMMARYBackground: In 2013, the German Standing Committee on Vaccination (Stän-dige Impfkommission, STIKO) recommended rotavirus (RV) vaccination for all infants while stating that this mildly increased the risk of intussusception, a potentially life-threatening event. Since this recommendation was issued, multiple observational studies on this topic designed as self-controlled case series (SCCS) have been published. The SCCS design is particularly suitable for the study of rare adverse effects of medications.

show abstract

mentioning

confidence: 99%

Risk of Intussusception After Rotavirus Vaccination

Koch¹,

Harder²,

Kries³

et al. 2017

Deutsches Ärzteblatt International

View full text Add to dashboard Cite

show abstract

“…The risk of intussusception with both current RVA vaccines, RV5 and RV1, was evaluated pre-licensure in clinical trials of 60,000-70,000 infants each (designed to assess a risk similar to RotaShield) and no risk was observed. In recent months, vaccine safety came under scrutiny after a post-licensure evaluation identified a short-term foursix-fold elevated relative risk of intussusception in the first-seventh days following dose 1 of RV1 in Mexico (Colindres 2010) and with both RV1 and RV5 in Australia (Buttery et al 2011). These risks are substantially lower than the 30-fold increased risk in the first week after dose 1 of RotaShield (WHO 2010).…”

mentioning

confidence: 99%

Reduction in morbidity and mortality from childhood diarrhoeal disease after species A rotavirus vaccine introduction in Latin America : a review

Desai

Oliveira

Parashar

et al. 2011

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

Countries in Latin America were among the first to implement routine vaccination against species A rotavirus (RVA). We evaluate data from Latin America on reductions in gastroenteritis and RVA disease burden following the introduction of RVA vaccine. Published literature was reviewed to identify case-control studies of vaccine effectiveness and population-based studies examining longitudinal trends of diarrhoeal disease reduction after RVA vaccine introduction in Latin American countries. RVA vaccine effectiveness and impact on gastroenteritis mortality and hospitalization rates and RVA hospitalization rates are described. Among middle-income Latin American countries with published data (Mexico, Brazil, El Salvador and Panama), RVA vaccine contributed to a gastroenteritis-associated mortality reduction of 22-41%, a gastroenteritis-associated hospitalization reduction of 17-51% and a RVA hospitalization reduction of 59-81% among children younger than five years of age. In Brazil and El Salvador, case-control studies demonstrated that a full RVA vaccination schedule was 76-85% effective against RVA hospitalization; a lower effectiveness of 46% was seen in Nicaragua, the only low-income country with available data. A growing body of literature offers convincing evidence of "real world" vaccine program successes in Latin American settings, which may be expanded as more countries in the region include RVA vaccine in their immunization programs

show abstract

“…Although no link was detected for the two current vaccines prior to being licensed, careful monitoring of their routine use in the USA, 7 Australia, 8 Mexico 9 and Brazil 10 has suggested that there may still be a weak temporal association. However, with this risk estimated to be in the region of one additional intussusception event per 50-100 000 vaccinations, it is now considered firmly outweighed by the benefits of vaccination.…”

Section: Safetymentioning

confidence: 99%